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A B S T R A C T
The Chromobox protein homolog 7 (CBX7) belongs to the Polycomb Group (PcG) family, and, as part of the
Polycomb repressive complex (PRC1), contributes to maintain transcriptional gene repression. Loss of CBX7
expression has been reported in several human malignant neoplasias, where it often correlates with an advanced
cancer state and poor survival, proposing CBX7 as a candidate tumor-suppressor gene in cancer progression.
Indeed, CBX7 is able to positively or negatively regulate the expression of genes involved in cell proliferation and
cancer progression, such as E-cadherin, cyclin E, osteopontin, EGR1.
To understand the molecular mechanisms that underlie the involvement of CBX7 in cancer progression, we
designed a functional proteomic experiment based on CHIP-MS to identify novel CBX7 protein partners. Among
the identiﬁed CBX7-interacting proteins we focused our attention on the Protein Arginine Methyltransferase 1
(PRMT1) whose critical role in epithelial-mesenchymal transition (EMT), cancer cell migration and invasion has
been already reported. We conﬁrmed the interaction between CBX7 and PRMT1 and demonstrated that this
interaction is crucial for PRMT1 enzymatic activity both in vitro and in vivo and for the regulation of E-cadherin
expression, an important hallmark of EMT.
These results suggest a general mechanism by which CBX7 interacting with histone modiﬁcation enzymes like
HDAC2 and PRMT1 enhances E-cadherin expression. Therefore, disruption of this equilibrium may induce im-
pairment of E-cadherin expression and increased cell migration eventually leading to EMT and, then, cancer
progression.
1. Introduction
Polycomb group (PcG) proteins are a class of structurally diverse but
functionally related epigenetic regulators involved in morphogenesis,
chromosome X-inactivation, haematopoiesis, stem-cell self-renewal,
cellular proliferation, senescence and tumorigenesis [1–3]. Biochemical
and genetic studies indicate that PcG proteins act as part of two major
multiprotein complexes referred as the Polycomb repressive complexes
1 and 2 (PRC1 and PRC2) that contribute to gene repression by in-
hibiting transcription initiation [4].
CBX7 (chromobox homolog 7), a component of the PRC1 complex,
belongs to a mammalian family of chromobox-containing proteins with
its amino-terminal region, between amino acids 10 and 46, containing a
“CHROMO” domain (Chromatin Organization Modiﬁer Domain, CD) that
binds methyl-lysine residues [5]. Several studies report a reduced ex-
pression of CBX7 in diﬀerent malignant neoplasias, such as thyroid [6],
colorectal [7], pancreatic [8], bladder [9], gastric [10], lung [11],
gliomas [12] and breast [13] carcinomas. Decreased CBX7 expression is
associated to a more aggressive phenotype and reduced survival, in-
dicating CBX7 as a candidate tumor-suppressor gene [14]. This role of
CBX7 in carcinogenesis was conﬁrmed by the generation of Cbx7 knock-
out mice (KO). Indeed, both heterozygous Cbx7+/− and homozygous
Cbx7−/− mice developed liver and lung adenomas and carcinomas [7].
Accordingly, MEFs derived from Cbx7-KO mice have a faster pro-
liferation rate with higher number of cells in S phase than wt MEFs
suggesting that Cbx7 negatively regulates G1/S transition [7].
Some of the mechanisms by which the lower expression of CBX7
contributes to cancer progression have already been unveiled. CBX7
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negatively regulates the expression of CCNE1, the gene coding for cy-
clin E, a regulator of cell cycle crucial for the G1/S transition, coun-
teracting the positive regulation exerted by HMGA1 proteins [7,11],
and thereby modulating cell proliferation. By a very similar mechanism,
CBX7 also negatively modulates the expression of SPP1 gene encoding
the osteopontin protein, a chemokine promoting cell migration and,
then, associated with cancer progression [15,16].
Furthermore, it was reported that CBX7 positively regulates E-cad-
herin gene (CDH1) expression through the interaction with histone
deacetylase 2 (HDAC2) [17]. Indeed, CBX7 physically interacts with
HDAC2 and reduces its negative activity on the CDH1 promoter, then
positively regulating the expression of the CDH1 gene [17]. It is note-
worthy that CDH1 is one of the caretaker genes of the normal epithelial
phenotype and the loss of its expression leads to the critical event of the
epithelial-to-mesenchymal transition (EMT). More recently, it was also
reported that the restoration of CBX7 expression increases the sus-
ceptibility of human lung carcinoma cells to irinotecan treatment [18].
On this ground, we envisaged the hypothesis that CBX7 counteracts
cancer progression also interacting with other proteins, thereby reg-
ulating the expression of other cancer-related genes. A comprehensive
investigation of CBX7 biological functions was performed by functional
proteomic experiments using a CHIP-MS based approach to im-
munoprecipitate V5-tagged CBX7 with the aim to identify new potential
CBX7-interacting candidate proteins [19,20]. Among several CBX7
protein partners, we focused our attention on the prevalent protein
arginine methyltransferase 1 (PRMT1). Indeed, several studies under-
line a critical role for PRMT1 deregulation in cancer since its over-
expression has been described in several carcinomas including colon
[21], breast [22], bladder [23], head and neck [24], lung, acute mye-
loid leukemia and mixed lineage leukemia [25,26]. Proteins belonging
to PRMTs group are able to transfer methyl groups from the ubiquitous
cofactor S-adenosyl-L-methionine (AdoMet) to the arginine residues of
many histones and nuclear/cytoplasmic proteins. In particular, PRMT1
catalyzes the formation of H4R3me2a and H2AR11me1 on the histone
proteins with a signiﬁcant preference for arginine residues ﬂanked by
one or more glycine residues [26–29]. Epigenetic regulation is funda-
mental to the dynamic control-balance between stability and reversi-
bility in gene expression projects. Post-translational modiﬁcation of
histones by methylation is an essential and common type of chromatin
modiﬁcation that is known to inﬂuence biological processes in the
context of development and cellular responses. However, it is a crucial
point that histone marks have context-dependent functions on tran-
scription. In fact, there are examples where the same modiﬁcations can
be associated with opposing eﬀects on transcription [30].
We conﬁrmed the interaction between CBX7 and PRMT1 by co-
immunoprecipitation and demonstrated that this interaction occurred
at the CDH1 promoter, being crucial for regulating both PRMT1 enzy-
matic activity and CDH1 expression. Indeed, we were able to demon-
strate that CBX7 decreases the catalytic activity of PRMT1 at Arg3 of
Histone H4 both in vitro and on the CDH1 promoter. These data suggest
that CBX7 contribute to the transcription of CDH1 also by interacting
with the mehyltransferase and impairing enzymatic activity of PRMT1.
2. Materials and methods
2.1. Cell culture, vector and transfection
HEK293 cell line was grown in DMEM (Life Technologies, Grand
Island, NY), instead A549 and HeLa in RPMI (Life Technologies). Both
medium were supplemented with 10% fetal bovine serum, 1% L-glu-
tamine 10mM, 1% penicillin/streptomycin (Life Technologies). All cell
lines were maintained at 37 °C under 5% CO2 atmosphere.
HeLa cells were transfected by using Fugene HD reagent (Promega,
Fitchburg, WI), while the Neon Electroporation System (Life
Technologies) was used for the HEK293 cells, and LIPO2000 (Life
Technologies) for A549 clones (EV4, C2 and C4), according to
manufacturer's instructions.
The expression vectors encoding the CBX7 protein fused to V5 or HA
epitope (V5-CBX7 or HA-CBX7) have been previously described [17].
The vector expressing the PRMT1 protein was provided by Geneco-
poeia™ (MYC-tagget-PRMT1). GST fusion proteins were constructed by
cloning the human cDNA sequence of CBX7 in a pGEX4T-1 vector
(Promega) as previously described [17]. For all transfections, the total
amount of the transfected DNA was balanced with the empty vector.
2.2. Luciferase assays
1.5× 105 HeLa cells were seeded in 6-well plate, transfected with
50 ng of the CDH1- luciferase reporter gene and expression vectors
encoding the CBX7 and PRMT1 proteins. 48 h after transfection, cell
extracts were prepared and the luciferase activity was measured by
using a Lumat LB9507 luminometer (Berthold Technologies, Bad
Wildbad, Germany) and the Dual-Luciferase Reporter System kit
(Promega). A vector expressing Renilla gene under the control of the
cytomegalovirus (CMV) promoter was used to normalize transfection
eﬃciency. For all transfections, the total amount of the transfected DNA
was balanced with the empty vector.
2.3. RNA extraction and quantitative RT-qPCR
Total RNA was extracted from cell lines by using Trizol reagent (Life
Technologies), according to manufacturer's instructions. 1 μg of total
RNA was used to obtain the cDNA with the QuantiTect Reverse
Transcription Kit (Qiagen). RT-qPCR analysis was carried out in 96-well
plates with the CFX 96 thermocycler (Bio- Rad, Hercules, CA) by using
20 ng of each cDNA and Sybr Green (Applied Biosystems, Foster City,
CA). Detailed primer sequences are available as Supplementary
Materials and Methods. Relative Expression was calculated according to
the 2−ΔΔCt formula and expression value of controls was set equal to 1
[31].
2.4. Protein extraction, Western blot analysis, immunoprecipitation and
GST pull down experiments
Total protein extracts were obtained by using the JS lysis buﬀer
(20mM Tris-HCl pH 7.5, 5 mM EDTA, 150mM NaCl, 1% Nonidet P40)
completed with a mix of inhibitors of proteases and phosphatases. The
extracted proteins were separated by SDS-PAGE and then transferred
onto Protran membranes (Perkin Elmer, Boston, MA). Membranes were
blocked with BSA or 5% non-fat milk and then incubated with the
following antibodies: anti-V5 (Invitrogen, Carlsband, CA, R960), anti-
MYC tag (Abcam, ab9132; Millipore 05-724), anti-PRMT1 (Millipore,
07–404), anti- γ-vinculin (Santa Cruz, sc-7649), anti-GAPDH (Santa
cruz, sc-32233), anti-α-Tubulin (Sigma, T5168), anti-γ-Tubulin (Santa
cruz, sc-17787). Membranes were then incubated with horseradish
peroxidase-conjugated secondary antibody (1:3000) for 60min at room
temperature and the signals were detected by enhanced chemilumi-
nescence (ECL) detection system (Thermo Fisher Scientiﬁc, Inc.,
Waltham, MA). Immunoprecipitation (IP) procedures were carried out
as reported elsewhere [17]. Antibodies used for IP with untransfected
cells were anti-CBX7 (Abcam ab-21873), anti- PRMT1 (Millipore 07-
404), for IP in transfected cells were anti-V5 (Abcam ab-1229), eluated
by V5-peptide (Abcam ab-15829).
2.5. Chromatin immunoprecipitation and mass spectrometry (ChIP-MS)
assays
ChIP-MS experiments (ChIP-MS) were performed in HEK293 cells,
transiently transfected with V5-tagged CBX7 (V5-CBX7) and the same
cell line transfected with an empty vector used as control [32,33]. Cells
were incubated in 50mM HEPES pH 7.5, 100mM NaCl, 1 mM EDTA,
0.5 mM EGTA and formaldehyde at a ﬁnal concentration of 0.75% at
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room temperature for 20min and the reaction was stopped by adding
glycine at a ﬁnal concentration of 0.125M. The protein nuclear extracts
were prepared as reported [32]. Brieﬂy, cells were lysed by using a
cytosolic buﬀer (50mM HEPES pH 7.5, 140mM NaCl, 1 mM EDTA,
10% glycerol, 0.5% NP-40, 0.25% Triton X100 and protease inhibitors),
thus obtaining the cytosolic extracts that were discarded; the remaining
pellets were washed in 10mM Tris-Cl pH 8.0, 200mM NaCl, 1 mM
EDTA, 0 .5mM EGTA and protease inhibitors, and ﬁnally lysed in buﬀer
containing 10mM Tris-Cl pH 8.0, 10mM NaCl, 1 mM EDTA, 0 .5mM
EGTA, 0.1% Na-Deoxycholate, 0.5% N-laurylsarcosine and protease
inhibitors, by sonicating several times for 10min at maximum settings
to obtain fragments between 400 and 600 bp. Then, Triton X-100 was
added to sample and control up to a ﬁnal concentration of 1%. The
protein samples were pre-cleared by a o.n. incubation at 4 °C on protein
A-magnetic beads (Life Technologies) previously treated with a
Blocking Solution (1X PBS, 0.5% BSA w/v). The pre-cleared extracts
were then imunoprecipitated with anti-V5 antibody (Ab15828 Abcam)
and protein A-magnetic beads. Following washing steps, the elution of
protein complex has been carried out contemporaneously to the de-
cross linking process adding de-cross linking/elution buﬀer 1X (250mM
Tris-HCl pH 8.8, 2% SDS, 0.5 M β mercaptoethanol) and incubating at
95 °C for 20min. 4/5 in volume of ﬁnal sample were employed for the
proteomic assay while 1/5 for the PCR.
The protein samples for proteomics analysis were separated by SDS-
PAGE and the gel was stained by colloidal blue comassie. Sample and
control lanes were cut in 1mm slices and the protein bands digested by
trypsin as reported [20,34,35]. The peptide mixtures were then freeze-
dried and re-suspended in 10ml of 0.2% Formic Acid for the nanoLC-
MS/MS analysis. Nano-Liquid Chromatography Tandem Mass Spectro-
metry (nanoLC-MS/MS) analyses were performed on a CHIP MS Ion
Trap XCT Ultra equipped with a capillary 1100 HPLC system and a chip
cube (Agilent Technologies, Palo Alto, CA). nanoLC-MS/MS raw data
were employed for protein identiﬁcation by using a licensed Mascot
software (Matrix Science, Boston, USA) to search in database containing
only human protein sequences [34,35].
2.6. ChIP and re-ChIP assays
ChIP and re-ChIP experiments were performed as reported else-
where [11,17]. Brieﬂy, 48 h after transfection, 5× 106 HEK 293 cells
were cross-linked to ﬁx the DNA-protein complexes using 1% for-
maldehyde at room temperature for 10min and the reaction was then
stopped by adding glycine at a ﬁnal concentration of 0.125M. Cells
were lysed in 300 μl of buﬀer containing 10mM EDTA, 50mM Tris-HCl
pH 8.0, 1% SDS and protease inhibitors and then sonicated three times
for 10 cycles (30′ ON, 30′ OFF) at maximum settings (BioruptorTM Next
Gen, Diagenode Inc., Denville, NJ), obtaining fragments between 0.3
and 1.0 kb. After centrifuging samples at 14000 rpm for 15min at 4 °C,
3% of supernatant amount was used as control of the total chromatin
obtained (input), and the remaining part of the sample was diluted 2.5-
fold in IP buﬀer (100mM NaCl, 2 mM EDTA pH 8.0, 20mM Tris-HCl
pH 8.0, 0.5% Triton X-100 and protease inhibitors). After 3 h of pre-
clearing at 4 °C with protein A- or protein G-Sepharose saturated with
salmon sperm (Millipore, Billerica, MA), samples were mixed overnight
at 4 °C with the following antibodies: anti-V5 (Ab15828 Abcam), anti-
V5 (Sigma, V8137), anti-MYC tag (Abcam, ab9132), anti-H4R3me2a
(Active motif, 39,705), anti-H3K27me3 (Millipore, 07–449), normal
mouse IgG (sc-2025, Santa Cruz Biotechnology, Inc.), normal rabbit IgG
(sc-2027, Santa Cruz Biotechnology, Inc.). Subsequently, the DNA-
protein-antibodies complexes were immunoprecipitated with the pro-
teins A/G previously used and then the chromatin was released from
the beads through 30min incubation with 250 μl of 1% SDS, 0.1 M
NaHCO3 at 37 °C and ﬁnally with 200 nM NaCl at 65 °C overnight.
Subsequently, 10 μl of 0.5mM EDTA, 20 μl of 1M Tris-HCl pH 6.5 and
20 μg of Proteinase K were added to the reaction tube and then the
complexes were incubated for 1 h at 45 °C. DNA from chromatin
immunoprecipitated was puriﬁed by phenol/chloroform extraction
(Life Technologies) and precipitated by adding two volumes of ethanol
and 0.1 M CH3COONa.
IgG were used as non speciﬁc control and input DNA values were
used to normalize the values from qChIP samples. The percentage of IP
chromatin was calculated as 2−ΔΔCt. ΔCt is the diﬀerence between Ct
(sample) and Ct (input), while ΔΔCt is the diﬀerence between ΔCt
(sample) and ΔCt (mean value of IgG). So, the IgG are set equal to 1
[31,36,37]. This input sample represents the amount of chromatin used
in the ChIP. By this method, signals obtained from the ChIP are sub-
tracted by those obtained from an input sample. In our experiments 3%
of starting chromatin is used as input. Raising 2 to the DCt power
yielded the relative amount of PCR product. The relative abundance of
immunoprecipitated chromatin was expressed as percentage of binding
of interested promoter compared to the input. For Fig. 3C the re-
presentation the value of empty vector (immunoprecipitated by Ab)
was set to 1 as mean value of all samples. All ChIP data were resulted by
more independent experiments, and for each experiment qPCR assay
was performed at least in triplicate. Detailed primer sequences are
available as Supplementary Materials and Methods.
2.7. In vitro methylation assay
The methylation reaction was conducted in 40ml of PBS buﬀer
(Euroclone) for 60min at 37 °C incubating recombinant PRMT1 (3mg)
with 4mg of core histones (Millipore) in presence of 5mM AdoMet
(Sigma Aldrich) and 4mg of GST-CBX7 (Abnova); the same reaction,
carried out in absence of CBX7, constituted the control. The reactions
were stopped by Laemli buﬀer addition and the samples were then
fractionated by SDS-PAGE on a 15% gel. Protein bands corresponding
to H4 histone were excised from the gel, destained with acetronitrile/
ammonium bicarbonate 0 .1M and hydrolysed by trypsin for 2 h at
37 °C. The hydrolysis shorter time has been previously set up on H4
histone thus to control the proteolysis events at N-terminus domain,
rich of basic residues, and to obtain longer peptides than those expected
by an extensive tryptic hydrolysis [34,35].
Peptide mixtures were analyzed by LC-MS/MS on a LTQ-Orbitrap
XL mass spectrometer (ThermoFisher Scientiﬁc) equipped with a nano-
electrospray ion source and coupled with a nanoEasy-LC II capillary
HPLC system (Proxeon Biosystem). Samples were injected onto a ca-
pillary chromatographic system consisting of a 2 cm length trapping
column (C18, ID 100um, 5um) and a 10 cm C18 reverse phase silica
capillary column (ID 75um, 3um) (ThermoFisher Scientiﬁc). A gradient
of 125min of acetonitrile eluents was used for separation (0.3 μL/min
ﬂow rate). MS analysis was performed with a resolution set to 30,000,
and mass range from m/z 300 to 1800 Da. The ﬁve most intense pep-
tides ions with 2, 3 and 4 charged residues were selected and frag-
mented in the ion trap. All MS/MS samples were analyzed using li-
censed Mascot software (Matrix Science) to search in a restricted
database containing only chicken histone sequences. Searches were
performed up to 9-missed cleavages, allowing Acetyl (Protein N-term)
as ﬁxed modiﬁcation and Acetyl (K), Dimethyl (K), Dimethyl (R),
Methyl (K), Methyl (R), Oxidation (M), as variable modiﬁcations.
2.8. Cell migration assay
Transwell motility assays were performed using 8 μm pore, 6.5
polycarbonate transwell ﬁlter (Corning Costar Corp., Cambridge, MA).
24 h after transfection, 2.5× 104 A549 cells were suspended in 200ml
serum-free medium and seeded on the upper surface of the ﬁlters and
allowed to migrate toward 300ml of 10% FBS-containing medium in
the bottom compartment. Moreover, 2.5× 104 A549 cells were plated
in a 96-well plate in triplicate and treated with CellTiter96 Aqueous
One (Promega) to conﬁrm that we used the same number of cells for
each condition. After additional 24 h, transwell ﬁlters were washed
three times with PBS at room temperature and cells migrated to the
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underside of ﬁlter were ﬁxed and stained with crystal violet solution
(0.1% crystal violet, 20% methanol). Cells remaining on the upper
surface were removed with a cotton swab. In order to exactly quantify
crystal violet staining, samples were de-stained with 0.1% SDS in
300ml of PBS, the absorbance of eluates were read at 595 nm in a
microplate readers (LX 800, Universal Microplate Reader, Biotek,
Winooski, VT) and then normalized with CellTiter values. Extracted
RNA and protein were analyzed to evaluate the expression of the
transfected vectors.
2.9. Statistical analysis
D'Agostino-Pearson or KS tests were used to evaluate the statistical
distribution of samples, and the ANOVA (parametric or non-para-
metric) was used to identify statistical signiﬁcance of the obtained data.
For comparison of two groups unpaired t-test was used. In all the ex-
periments, the signiﬁcance was considered for p < 0.05 (*) or
p < 0.01 (**). Data are reported as mean values± standard error of
mean (SEM) for multiple experiments, and as mean values± standard
deviation (SD) for single experiment.
3. Results
3.1. Identiﬁcation of CBX7 interacting proteins and target genes
The organization and functions of CBX7-containing protein com-
plexes were investigated by a Chromatin Immunoprecipitation assay
coupled with mass spectrometry (ChIP-MS) [32,33]. This experiment
allowed us to identify both the DNA regions speciﬁcally bound by the
CBX7 complexes and the individual protein components eﬀectively
belonging to these complexes. ChIP-MS experiments were performed in
HEK293 cells transiently transfected with V5-tagged CBX7 (V5-CBX7).
The same cell line transfected with an empty vector was used as control.
Protein complexes were covalently linked to DNA sequences and
immunoprecipitated by using antibodies against the V5 epitope.
Samples were also immunoprecipitated with aspeciﬁc IgG antibodies as
a control for the PCR-samples. The immunoprecipitated material com-
prising V5-CBX7 containing proteins-DNA complexes was employed for
both Polymerase Chain Reaction (PCR) assay to verify the binding of
CBX7 to the promoters of known target genes and for proteomic ana-
lyses to identify individual protein components.
The DNA fragments released by the immunocomplexes were ana-
lyzed by qPCR assay using speciﬁc primers for the human E-cadherin
(CDH1), cyclin E (CCNE1) and p16 (CDKN2A) promoters, that have
already been reported as CBX7 target genes. As shown in Fig. 1A, the
amount of immunoprecipitated (IP) chromatin ampliﬁed by PCR was
higher in the cells transfected with V5-CBX7 vector than in those
transfected with the empty vector, conﬁrming that CBX7 speciﬁcally
binds to the CDH1, p16 and CCNE1 promoters [11,17].
The elution of protein components was carried out at the same time
of the de-cross linking process, as described in Material and Methods
section. The V5-CBX7 immunoprecipitated protein complexes and the
corresponding control were fractionated onto a 4–12% gradient SDS-
PAGE. The entire gel lanes were cut into slices and each gel slice was
submitted to in situ tryptic digestion [34–36]. The resulting peptide
mixtures were directly analyzed by liquid chromatography tandem
mass spectrometry (LC-MS/MS) and identiﬁed by the MASCOT protein
database search [34,35]. Proteins identiﬁed both in the control and in
the sample lanes were discarded, whereas those proteins solely occur-
ring in the V5-CBX7 transfected sample and absent in the control were
considered as putative CBX7 interactors (Table 1). Among the putative
CBX7 partners, several proteins involved in DNA- or RNA binding
(PUF60, PRPF19, HNRNPD, PCBP1) and chromatin modiﬁcation
(HDAC2, PRMT1) were identiﬁed as well as the binding to HDAC2, that
has already been reported [17,38].
Surprisingly, no other PRC1 components have been identiﬁed in the
proteomic experiments except for the SCML2 subunit belonging to
Polycomb family. However, in a diﬀerent experiment, V5-CBX7 im-
munoprecipitated protein complexes were fractionated by ultra-
centrifugation on glycerol-gradient and the fractions positive for V5-
CBX7 were submitted to protein identiﬁcation (data not shown). A
number of PRC1 components, but not PRMT1, has been identiﬁed
among CBX7 interactors whereas when PRMT1 was present no PRC1
proteins were found suggesting that the interaction of PRMT1 with
CBX7 might be independent from PRC1.
Among the putative CBX7 interacting candidates, we focused our
attention on the Protein Arginine Methyltransferase 1 (PRMT1) because
of the critical role of its deregulation in cancer [21–26]. Moreover,
PRMT1 is known to catalyze the formation of H4R3me2a and
H2AR11me1 on the histone proteins with methylation of H4R3 being
highly related to tumor grade and used to predict cancer recurrence
[27–29].
The interaction between endogenous CBX7 and PRMT1 was con-
ﬁrmed by co-immunoprecipitation experiments. Nuclear extracts from
wild type HEK293 cells were precleared with IgG agarose and im-
munoprecipitated by using anti-CBX7 and anti-PRMT1 antibodies.
Immunoprecipitation experiments were separated on SDS-PAGE and
western blots were probed with anti-PRMT1 and anti-CBX7, respec-
tively, conﬁrming the interaction between PRMT1 and CBX7 proteins,
as shown in Fig. 1B.
In addition, HEK293 cells were transiently transfected with V5-
CBX7 and MYC-PRMT1 and total protein extracts were im-
munoprecipitated using anti-V5 antibody. Immunoprecipitated proteins
were separated on SDS-PAGE and western blots were probed with anti-
MYC and anti-V5 for detection of the co-immunoprecipitated PRMT1
protein to verify the interaction between CBX7 and PRMT1. The bands
showing the electrophoretic mobility expected for MYC-PRMT1 and V5-
CBX7 were clearly revealed by anti-MYC and anti-V5 antibody in the
same lane (Fig. 1C), conﬁrming the interaction between CBX7 and
PRMT1.
The speciﬁcity of this interaction was conﬁrmed by pull-down as-
says by incubating HEK293 total protein extracts either with a re-
combinant form of CBX7 fused to GST (GST-CBX7) immobilized onto
glutathione-conjugated agarose beads or the GST protein alone as
control. GST-CBX7 bound proteins were eluted by an excess of free
glutathione. Fig. 1D shows the corresponding western blot analysis
performed with anti-PRMT1 antibody where a strong band with the
electrophoretic mobility of PRMT1 was clearly detected only in the
sample incubated with GST-CBX7, thus conﬁrming the interaction be-
tween PRMT1 and CBX7.
3.2. CBX7 interacts with PRMT1 on the E-cadherin promoter
To investigate whether the interaction between CBX7 and PRMT1
takes place on the CDH1 promoters, we carried out chromatin im-
munoprecipitation (ChIP) experiments in HEK293 cells.
First, we validated the binding of endogenous CBX7 on speciﬁc DNA
promoters. The DNA-protein complexes were ﬁxed, subjected to pre-
clearing with IgG and then immunoprecipitated by the anti-CBX7 an-
tibody. Samples were also immunoprecipitated with aspeciﬁc IgG an-
tibodies as a control. Chromatin was then released by the im-
munocomplexes and analyzed by qPCR assay using speciﬁc primers for
the human CDH1 and CCNE1 promoter. As shown in Fig. 2A, the
amount of immunoprecipitated chromatin ampliﬁed by qPCR was
higher in the samples immunoprecipitated by using anti-CBX7 antibody
than in the control conﬁrming that endogenous CBX7 binds the CDH1
and CCNE1 promoters.
Second, we transiently transfected HEK293 cells with either in-
dividually V5-CBX7 or MYC-PRMT1 or both vectors (Fig. 2C). The DNA-
protein complex from cells over expressing V5-CBX7 were ﬁxed and
then immunoprecipitated by using antibodies against the V5 epitope.
Samples were also immunoprecipitated with aspeciﬁc IgG antibodies as
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a control. Chromatin was then released by the immunocomplexes and
analyzed by qPCR assay using speciﬁc primers for the human CDH1
promoter. As shown in Fig. 2B the amount of immunoprecipitated
chromatin ampliﬁed by qPCR was higher in the cells transfected with
V5-CBX7 than in the control, as already reported [17].
Interestingly, when both V5CBX7 and MYC-PRMT1 were con-
temporaneously overexpressed (Fig. 2C), the amount of IP chromatin
was lower than in the presence of CBX7 alone (Fig. 2B), indicating that
the contemporary overexpression of CBX7 and PRMT1 decreases the
binding of CBX7 to the CDH1 promoter. These results indicate that the
binding of CBX7 to CDH1 promoter is compromised by PRMT1 over-
expression, thus suggesting a reduced interaction or accessibility for
DNA binding when the proteins interact.
When HEK293 cells were transiently transfected with both V5-CBX7
and MYC-PRMT1 vectors, a ReChIP experiment was carried out by
immunoprecipitating chromatin with anti-V5 ﬁrst (Supplementary
Figure 1) and then with anti-MYC antibodies. The results reported in
Fig. 2D clearly indicated a large increase in the amount of im-
munoprecipitated chromatin ampliﬁed by qPCR following the ReChIP
procedure demonstrating that the CBX7/PRMT1 interaction occurred at
the CDH1 promoter.
Finally, no ampliﬁcation was observed when the chromatin was
immunoprecipitated with anti-MYC antibodies in HEK293 over ex-
pressing MYC-PRMT1, indicating that PRMT1 alone was not able to
bind the CDH1 promoter (Fig. 2E).
3.3. H4R3 dimethylation is aﬀected by CBX7 in vitro
PRMT1 is known to methylate Arg3 of histone H4 (H4R3) and this
asymmetric dimethylation aﬀects transcription [28–30]. However, the
downstream consequences of the methylation event are poorly under-
stood in many cases. Indeed, recent studies report that eﬀects of me-
thylation can be also context dependent [30].
To investigate the putative biological eﬀect of the CBX7/PRMT1
Fig. 1. CBX7 binds CDH1, CCNE1 and CDKN2A promoters and interacts with PRMT1. A. HEK293 cells were transiently transfected with either a vector
expressing V5-CBX7 (CBX7) protein or an empty vector (EV). The chromatin was immunoprecipitated by using antibodies (Ab) against the V5 epitope. IgG were used
as negative control (IgG). The IP chromatin was analyzed by qPCR assay performed with primers speciﬁc for the CDH1, CCNE1 and CDKN2A promoters. B. Nuclear
extracts (NE) from HEK293 cells were subjected to pre-clearing (lane 1 and 2, respectively of Ab CBX7 and Ab PRMT1) and then immunoprecipitated with CBX7
antibody (Ab CBX7) and PRMT1 antibody (Ab PRMT1). Immunocomplexes were analyzed by Western blot with anti-CBX7 and anti-PRMT1 antibodies. Input: NE by
HEK293 cells. C. HEK293 cells were transiently transfected with empty vector (lane 2) or V5-CBX7 and MYC-PRMT1 (lane 3) and co-immunoprecipitation ex-
periments were carried out starting from total cellular extracts (TCE) by using anti-V5 antibodies (lane 6 and 10). IgG were used as an unrelated antibody (lane 4 and
8). Immunocomplexes were analyzed by Western blot with anti-MYC and anti-V5 antibodies. Input: TCE by cells transfected with empty vector (−) or V5-CBX7 and
MYC-PRMT1 vector (+). D. GST pull-down assay was performed incubating HEK293 total cellular extracts either with GST or recombinant GST-CBX7 proteins. The
ﬁlter was incubated with an anti-PRMT1 antibody. Input: TCE of HEK293 cells. CRTL: positive control expressing PRMT1 protein.
Table 1
Proteins identifyed by CBX7/ChIP-MS.
Protein name (UniProt) Gene Peptides MW (kDa) UniProt code
Sex comb on midleg-like protein 2 SCML2 3 78 Q9UQR0
Exosome complex component RRP45 EXOSC9 5 40 Q06265
Poly(U)-binding-splicing factor PUF60 PUF60 5 58 Q9UHX1
Histone deacetylase 2 HDAC2 3 65 Q92769
T-complex protein 1 subunit theta CCT8 5 60 P50990
Pre-mRNA-processing factor 19 PRPF19 3 56 Q9UMS4
Protein arginine N-methyltransferase 1 PRMT1 11 40 Q99873
Poly(rC)-binding protein 1 PCBP1 7 38 Q15365
Heterogeneous nuclear ribonucleoprotein D0 HNRNPD 3 36 Q14103
Chromobox protein homolog 7 CBX7 9 28 O95931
BTB/POZ domain-containing protein KCTD12 KCTD12 8 36 Q96CX2
Nucleophosmin NPM1 3 31 P06748
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Fig. 2. CBX7 physically interacts with PRMT1 on the CDH1 promoter. A. HEK293 cells were crosslinked, sonicated and subjected to pre-clearing with IgG. Then,
immunocomplexed were immunoprecipitated with IgG and CBX7 antibody. The chomatin was analyzed by qPCR assay performed in triplicate with primers speciﬁc
for the human CDH1 and CCNE promoters. The sample immunoprecipitated with IgG was set to 1. The shown results represent mean values± SD of a representative
experiment. B. HEK293 cells were transiently transfected with either V5-CBX7 and/or MYC-PRMT1 vectors or an empty vector. The chromatin was im-
munoprecipitated (IP) by using antibodies against V5/HA epitope. The IP chromatin was analyzed by qPCR assay performed in triplicate with primers speciﬁc for the
human CDH1 promoter. IgG were used as negative control. The sample immunoprecipitated with IgG was set to 1. The shown results represent mean values± SEM of
ﬁve independent experiments. C. Immunoblot analysis showing representative samples transfected with V5-CBX7 and MYC-PRMT1. γ-tubulin was used as control to
normalize the amount of protein loaded. CTRL: As positive control were used total cellular extracts expressing CBX7 or PRMT1 proteins. D. Re-chromatin im-
munoprecipitation experiments in which soluble chromatin immunoprecipitated with anti-V5 antibodies was re-immunoprecipitated with anti-PRMT1. IgG were
used as negative control and used to normalize the samples. The sample immunoprecipitated with IgG was set to 1. The shown results are the values of a re-
presentative experiment for the human CDH1 promoter. D'Agostino-Pearson tests were used to evaluate the statistical distribution of samples. Unparaired t-test:
*p < 0.05 E. HEK293 cells were transiently transfected with MYC-PRMT1 vectors or an empty vector. The chromatin was immunoprecipitated (IP) by using
antibodies against MYC tag epitope. The IP chromatin was analyzed by qPCR assay performed in triplicate with primers speciﬁc for the human CDH1 promoter. IgG
were used as negative control and was set to 1. The shown results represent mean values± SEM of two independent experiments.
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interaction on H4R3 dimethylation catalyzed by PRMT1, we evaluated
its enzymatic activity in the presence and in the absence of CBX7. The
core histone was incubated with recombinant PRMT1 and CBX7 using
AdoMet as methyl donor; the same reaction was performed in the ab-
sence of CBX7 as a control. Following the methylation reaction, the
histone mixture was fractionated by SDS-PAGE and the protein band
corresponding to histone H4 was excised from the gel and in situ hy-
drolysed with trypsin under strictly controlled conditions. In these ex-
perimental conditions, the enzymatic digestion released tryptic pep-
tides containing several missed cleavages and suitable in size for
eﬀective MS and MS/MS analyses. Accordingly, the LC-MS/MS analyses
of the corresponding peptide mixtures led to an almost complete
mapping of the histone H4 sequence (97% in the presence of CBX7 and
100% in the absence of CBX7). In both these samples the H4 N-terminal
sequence (peptide 1–23) was completely mapped revealing both un-
modiﬁed and diﬀerently acetylated peptides, including the N-terminal
amino-group, as already observed in a H4 untreated sample.
When only PMRT1 was present in the assay, three peptides were
found to map onto the N-terminal region of H4 histone, i.e. fragments
1–8, 1–12 and 1–16, all carrying both N-terminal acetylation and Arg3
dimethylation modiﬁcations as reported in Table 2. These peptides
were, then, selected to evaluate the eﬀect of CBX7 on PRMT1 di-
methylation activity. Fig. 3 (A, B) shows the LC-MS chromatograms of
dimethylated H4R3 1–8, 1–12 and 1–16 speciﬁc peptide ions extracted
from the total ion current of tryptic peptides of H4 treated with PRMT1
and AdoMet in the absence (panel A) and in the presence (panel B) of
CBX7. The ion current of the unmodiﬁed C-terminal peptide 68–77 is
reported for normalization. In the presence of CBX7 a decrease in the
intensity of the ion current associated to all the H4 dimethylated pep-
tides was clearly observed, demonstrating that the presence of CBX7
results in a inhibition of the PRMT1 methylation activity.
3.4. Eﬀects of CBX7 and PRMT1 on the methylation status of H4R3 in vivo
To investigate the in vivo eﬀect of CBX7/PRMT1 binding to the
CDH1 promoter on the methylation status of H4R3, we performed a
ChIP assay using antibody speciﬁc for the H4R3me2as (asymmetric
dimethylation of Histone H4 at Arg3). HEK293 cells were transiently
transfected with either individually V5-CBX7 or MYC-PRMT1 or both
vectors. The DNA-protein complexes were ﬁxed and then im-
munoprecipitated by using antibodies against the H4R3me2as. Samples
were also immunoprecipitated with aspeciﬁc IgG antibodies as a con-
trol. Chromatin was released by the immunocomplexes and analyzed by
qPCR assay using speciﬁc primers for the human CDH1 promoter. As
shown in Fig. 3C, the amount of immunoprecipitated chromatin am-
pliﬁed by qPCR was slightly lower in cells overexpressing CBX7 than in
the control, indicating a decrease in dimethylation of H4R3 in the
presence of an excess of CBX7. The amount of immunoprecipitated
chromatin in cells transfected with MYC-PRMT1 was higher than in the
control, indicating an increase of H4R3 dimethylation, as expected.
Finally, when both V5-CBX7 and MYC-PRMT1 were overexpressed,
the amount of immunoprecipitated chromatin ampliﬁed by qPCR was
largely decreased as compared to PMRT1 alone. These results clearly
demonstrate that CBX7 decreases the asymmetric methylation status of
H4R3 generated by PRMT1 at the CDH1 promoter accordingly to the
results of in vitro methylation assays.
3.5. CBX7 counteracts the negative transcriptional eﬀect of PRMT1 on
CDH1 promoter
Next, to analyze the eﬀects of the CBX7/PRMT1 complex on the
CDH1 promoter activity we performed a luciferase assay in the HeLa
cells transfected with a vector encoding the luciferase gene under the
control of the CDH1 promoter. HeLa cells were then transfected with
either individually HA-CBX7 or MYC-PRMT1 or both vectors. Fig. 4A
shows that CBX7 and PRMT1 displayed an opposite behavior in mod-
ulating CDH1 promoter activity. In the presence of CBX7 alone, the
luciferase expression was highly increased. On the contrary, PRMT1
clearly exerted a negative transcriptional eﬀect on CDH1 promoter as
luciferase gene expression was signiﬁcantly decreased by PRMT1 in a
dose-dependent manner. However, when both proteins gathered to-
gether at the CDH1 promoter, a partial rescue of the transcriptional
activity was obtained strongly depending on the amount of CBX7. These
results were conﬁrmed by evaluating luciferase gene expression in
samples transfected with increasing dose of PRMT1 where a clear de-
crease of CDH1 trancriptional activity could be observed according to
increasing amount of the methylatransferase (Fig. 4B). Expression of
CBX7 and PRMT1 was veriﬁed by western blot (Fig. 4C).
These results were also conﬁrmed by evaluating the expression of
CDH1 gene. HEK293 cells were transfected with either individually V5-
CBX7 or MYC-PRMT1 or both vectors and the expression of CDH1 was
measured by RT-qPCR assay using speciﬁc primers for the human CDH1
mRNA. According to previous results, CDH1 expression increased when
the cells were transfected with V5-CBX7 alone, while it decreased in the
presence of PRMT1 (Fig. 4D). A partial rescue of CDH1 expression
compared to that observed in the presence of PRMT1 alone could be
observed when both proteins were present, conﬁrming the eﬀects of the
CBX7/PRMT1 complex on the CDH1 promoter activity.
These results strongly suggest that CBX7 is able to counteract the
transcriptional negative eﬀect of PRMT1 on CDH1 expression.
3.6. Eﬀects of the CBX7/PRMT1 complex on cell migration
Since CBX7 and PRMT1 are involved in the regulation of CDH1
expression, we investigated whether CBX7 and PRMT1 might aﬀect cell
migration ability. Therefore, A549 cells, a human lung carcinoma cell
line, stably expressing empty (A549-EV4) or CBX7 (A549-C2 and A549-
C8) vectors were transfected with empty (pENTR) or interfering-PRMT1
(shPRMT1) vectors to silence PRMT1 expression [18,44].
The expression of CBX7 was evaluated by RT-qPCR (Fig. 5A)
whereas silencing of PRMT1 in A549 clones was monitored by both RT-
qPCR and immunoblotting (Fig. 5B, left and right panels). 24 h after
transfection, cells were seeded in a transwell and cell migration ability
was evaluated after additional 24 h. As shown in Fig. 5C and E, cells
expressing CBX7 (A549-C2 and A549-C8) or silenced for PRMT1 (EV4-
shPRMT1) alone showed a lower migration rate than the respective
control cells (EV4-pENTR), demonstrating that overexpression of CBX7
or silencing of PRMT1 showed the same eﬀect on cell migration rate.
Interestingly, A549-C2 and A549-C8 clones where PRMT1 was si-
lenced (shPRMT1) showed an analogous migration ability in compar-
ison to the respective controls, suggesting that the inhibition eﬀect of
CBX7 and the silencing of PRMT1 are not cooperative, as no additive
eﬀect could be observed on cell migration rate. These data were vali-
dated by the comparable expression of CDH1 in the same cells, EV4, C2
and C8, transiently transfected with pENTR or shPRMT1 (Fig. 5D). All
together these results reinforced the observation that CBX7 is able to
counteract the negative eﬀect of PRMT1 on CDH1 expression and cell
migration due to the inhibition of PRMT1 dimethylation activity.
Table 2
List of Peptides identiﬁed by in vitro methylation assay.
m/z
observed
M expected Peptide (start-
end)
Peptides sequences including PTMsa
408.7391 815.4636 [1–8] Acetyl-SG(Dimethyl)RGKGGK
586.3500 1170.6854 [1–12] Acetyl-SG(Dimethyl)RGKGGKGLGK
763.9473 1525.8800 [1–16] Acetyl-SG(Dimethyl)RG(Acetyl)
KGGKGLGKGGAK
a Post-translational modiﬁcations.
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4. Discussion
Epigenetic modiﬁcations, including those occurring on DNA and
histone proteins, control gene expression by establishing and main-
taining diﬀerent chromatin proﬁles. Arginine methylation is one of
several post-translational modiﬁcations (PTMs) occurring on histones,
catalyzed by a family of PRMTs (protein arginine methyltransferases).
This modiﬁcation is involved in the regulation of the epigenome largely
by controlling the recruitment of eﬀector molecules to chromatin.
Histone marks have context-dependent functions on transcription and,
indeed, arginine methylation associates with both active and repressed
chromatin status depending on the residue involved and the conﬁg-
uration of the deposited methyl groups. Histones are susceptible to
various PTMs including phosphorylation, methylation, acetylation and
ubiquitination whose individual eﬀect on transcription is not univocally
assessable [3,39,40]. Numerous histone modiﬁcations communicate
among themselves by inﬂuencing the presence of each other or by
collaborating to lead about a functional outcome. Histones can be post-
translationally modiﬁed to reorganize chromatin in many ways, in-
cluding already mentioned phosphorylation, ubiquitination, acetyla-
tion, and methylation, but also, with diﬀerent and speciﬁc combination
of sites, types and extents of histone modiﬁcations. In fact, the ‘Histone
Code Hypothesis’ suggests that changed combinations of histone mod-
iﬁcations may regulate chromatin structure and transcriptional status,
also in a context dependent manner [30,41].
Moreover, cross-talks can occur on the same histone (cis) or between
diﬀerent histones (trans), and it has been proposed that trans mechan-
isms could even involve more than one nucleosome [42]. The study of
Fig. 3. Eﬀect of CBX7 on the methylation status of H4R3 in vitro and in vivo. A, B. Ion extract chromatograms of dimethylated H4R3 1–8, 1–12 and 1–16 peptides
from the LC-MS total ion current of tryptic digest of H4 treated with PRMT1 and AdoMet in the absence (Panel A) and in the presence (Panel B) of CBX7. The ion
current of the C-terminal peptide 68–77 is also reported for normalization. C (left panel) HEK293 cells were transiently transfected with a vector expressing V5-CBX7
protein and/or MYC-PRMT1 protein or with an empty vector. The chromatin was immunoprecipitated (IP) by using antibodies against H4R3me2as and the presence
of H4R3 modiﬁcation was valutated on CDH1 promoter. IgG were used as negative control. The representation of the value of empty vector (immunoprecipitated by
Ab) was set to 1 as medium value of all samples transfected by empty vector. The shown results represent mean values± SEM of four independent experiments.
D'Agostino-Pearson tests were used to evaluate the statistical distribution of samples. Ordinary one-way Anova **p <0 .01. (right panel) Immunoblot analysis
showing representative samples transfected with V5-CBX7 and MYC-PRMT1. γ-tubulin was used as control to normalize the amount of protein loaded.
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Fig. 4. CBX7 counteracts the negative transcriptional eﬀect of PRMT1 on CDH1 promoter. A, B. HeLa cells were transfected with the E-cadherin-luc vector and with
single or both vectors expressing HA-CBX7 or MYC-PRMT1. The double-transfected samples had increasing doses of either HA-CBX7 or MYC-PRMT1 vector. The total
amount of the transfected DNA was balanced with the empty vector. Relative Luciferase Activity was calculated relative to that observed in cells transfected with the
E-cadherin-luc vector and the empty vector alone, assumed equal to 1. Values are the mean of eight independent experiments performed in triplicate± SEM. C.
Immunoblot analysis showing representative samples transfected with V5-CBX7 and MYC-PRMT1. α− tubulin was used as control to normalize the amount of
protein loaded. D (Left panel) HEK293 cells were transfected with single or both vectors encoding V5-CBX7 or MYC-PRMT1. The total amount of the transfected DNA
was balanced with the empty vector. Relative CDH1 mRNA expression represents values normalized to control cells transfected with the only empty vector, that was
set equal to 1. Values are the mean of six independent experiments performed in triplicate± SEM. D'Agostino-Pearson tests were used to evaluate the statistical
distribution of samples. Ordinary one-way Anova *p < 0.05, **p < 0.01. (Right panel) Immunoblot analysis showing representative samples transfected with V5-
CBX7 and MYC-PRMT1. γ-tubulin was used as control to normalize the amount of protein loaded. CTRL: positive control expressing CBX7 and PRMT1 proteins.
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these cross-talks has received great attention because the reading of
these modiﬁcations by diﬀerent eﬀectors inﬂuences gene expression,
and misinterpretation of these cross-talks by readers may trigger var-
ious diseases, including cancer [43,44]. All known cross-talk mechan-
isms described also for arginine methylation on H4 involve Arg3, and
speciﬁcally its dimethylated (asymmetric or symmetric) forms.
CBX7 is a Polycomb protein that positively or negatively modulates
the expression of several genes involved in development and diﬀer-
entiation by recognizing and binding speciﬁc histone modiﬁcation sites
on the chromatin structure [1,14]. Several studies have shown that the
loss of CBX7 expression correlates with poor prognosis in several cancer
tissues [6–13] and, more recently, with chemoresistance to anti-
neoplastic drugs [18] suggesting a critical role of CBX7 in cancer pro-
gression.
In order to better deﬁne the role and the molecular mechanisms of
CBX7 in cancer progression, we designed ChIP/MS-MS assays to iden-
tify CBX7 interacting proteins that bind speciﬁc DNA regions. Among
several identiﬁed CBX7 protein partners, we focused our attention on
PRMT1 protein that transfers methyl groups from the ubiquitous co-
factor S-adenosyl-l-methionine (AdoMet) to the arginine residues of
many histone and nuclear/cytoplasmic proteins. The presence of sev-
eral evidences correlating PRMT1 functions to the control of cell pro-
liferation and to the development and cancer progression has accounted
for this choice. Indeed, aberrant expression of PRMT1 has been ob-
served in several cancer tissues [21–26]. More recently, PRMT1 has also
been described as an important regulator of EMT acting by repressors of
CDH1 expression [45,46]. EMT is a complex phenomenon and an im-
portant driver of tumor invasion, and, then, of metastasis development.
A hallmark of EMT is considered the downregulation of CDH1 that
generally reinforces the destabilization of adherent junctions. Since
CBX7 positively regulates CDH1, we have proposed a pathway in which
CBX7 downregulated expression contributes to cancer progression by
decreasing CDH1 expression because of the lack of its inhibitory eﬀect
on HDAC2 activity on the CDH1 promoter [17].
Therefore, aiming to deﬁne the biological functions of the CBX7/
PRMT1 complex and the molecular mechanisms in cancer progression,
we demonstrate the contemporary presence of both proteins on the
CDH1 promoter by ChIP and ReChIP experiments. Moreover, the oc-
currence of the CBX7/PRMT1 complex on the CDH1 promoter de-
creases the methylation capabilities of PRMT1. Both in vitro experi-
ments by LC-MS/MS measurement of dimethylated H4 peptides and in
vivo ChIP assays with H4R3me2a antibodies reveal a lower modiﬁcation
level of H4R3 in presence of CBX7.
The modiﬁcation of H4R3me2as by PMRT1 and the CBX7/PMRT1
complex was demonstrated to aﬀect transcription. Using luciferase gene
reporter assays, we found that PRMT1 is able to reduce the activity of
the CDH1 promoter and that this negative regulation was inhibited by
the presence of CBX7 protein in a dose-dependent manner. These results
were further conﬁrmed by the analysis of CDH1 mRNA expression.
CDH1 expression decreased in the presence of PRMT1 but this negative
eﬀect was partially rescued in the presence of CBX7.
The ability of PRMT1 to increase H4R3me2as and CDH1 expression
in absence of its binding to CDH1 promoter is in agreement with pre-
vious published data that demonstrate that PRMT1 negative regulates
E-cadherin transcription through PRMT1-mediated Twist methylation,
without an its direct binding on E-cadherin promoter [45].
Moreover, it has been demonstrated that the Polycomb proteins can
regulate gene transcription in absence of the binding of the enzyme of
PRC1 complex to the DNA [3].
Consistently with the biological role of the CBX7-PRMT1 complex,
we showed that transfected cells with shPRMT1 displayed a lower mi-
gration ability than control cells. The migration rate of thyroid carci-
noma cells was analogously decreased in the presence of both CBX7 and
PRMT1, conﬁrming previous data on the opposite eﬀects of CBX7 and
PRMT1 in the regulation of CDH1 expression.
5. Conclusions
The overall model (summarized in Fig. 6), suggested by the data
reported here, seems to indicate that CBX7 physically interacts with
PRMT1, and that this interaction takes place on the E-cadherin promoter
where CBX7 counteracts the H4R3 dimethylation activity of PRMT1
leading to increased E-cadherin mRNA levels. Then, the association
between CBX7 and PRMT1 primarily serves to decrease methylation
and to increase chromatin association by PRMT1, eventually regulating
E-cadherin expression and preventing EMT.
Therefore, it can be assumed that a subtle cellular balance exists
between CBX7 and histone modiﬁcation enzymes like HDAC2 and
PRMT1. Then, a disruption of this equilibrium, due to a decreased ex-
pression of CBX7 in neoplastic tissues, may contribute to cancer pro-
gression inducing impairment of CDH1 expression and increased cell
migration eventually leading to EMT.
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Fig. 5. Eﬀects of the CBX7/PRMT1 on cell migration. A. A549 clones (EV4, C2 and C8), transiently transfected with pENTR or shPRMT1, were subjected to RT-qPCR.
Relative CBX7 mRNA expression represents values normalized to Empty vector clone (EV4), that was set equal to 1. Values are the mean of two independent
experiments performed in triplicate± SEM. D'Agostino-Pearson tests were used to evaluate the statistical distribution of samples. Ordinary one-way Anova
**p < 0.01. B. (left panel) A549 clones (EV, C2 and C8) were subjected to RT-qPCR. Relative PRMT1 mRNA expression represents values in cells transfected with
shPRMT1 normalized to respective cells transfected with pENTR vector, that was set equal to 1. Values are the mean of four independent experiments performed in
triplicate± SEM. D'Agostino-Pearson tests were used to evaluate the statistical distribution of samples. Kruskal-Wallis test *p < 0,05, **p < 0.01. (right panel) A
representative immunoblot analysis conﬁrming the reduced expression of PRMT1 after transfection with shPRMT1 in A549 clones (EV4, C2 and C8). GAPDH was
evaluated to normalize the amount of the protein used. C. A549 clones, stably transfected with empty vector (EV4) and CBX7 (C2 and C8), were re-transfected with
empty vector (pENTR) or interfering vector for PRMT1 (shPRMT1) and, then, cells were seeded in a transwell. Transwells were de-stained and cell migration rate was
evaluated by monitoring the crystal violet solution at 595 nm/cell tyter of plated cells. Values obtained were normalized with respect to control cells stably
transfected with the empty vector whose value was set equal to 1. Values are the mean of three independent experiments performed in triplicate± SEM. D'Agostino-
Pearson tests were used to evaluate the statistical distribution of samples. Ordinary one-way Anova *p < 0,05, **p < 0.01. D. A549 clones (EV, C2 and C8),
transiently transfected with pENTR or shPRMT1 were subjected to RT-qPCR. Relative CDH1 mRNA expression represents values normalized to Empty vector clone
(EV4), that was set equal to 1. Values are the mean of four independent experiments performed in triplicate± SEM. D'Agostino-Pearson tests were used to evaluate
the statistical distribution of samples. Ordinary one-way Anova **p < 0.01.E. Transwell pictures from a representative experiment in A549 clones (EV, C2 and C8)
transiently transfected with pENTR or shPRMT1. Magniﬁcation 40×.
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